ºÐÀÚÆó¾Ï ¿¬±¸È¸ Lung Cancer School 2022 : 2022-07-23±³À°ÀÏÀÚ : 2022-07-23
±³À°Àå¼Ò : SC CONVENTION 12Ãþ ¾Æ³ªÀ̽ºÈ¦
±³À°ÁÖÁ¦ :
Lung Cancer School 2022ÁÖÃÖ±â°ü : ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÐÀÚÆó¾Ï ¿¬±¸È¸
´ã´çÀÚ : ±è¹Ì¼±
¿¬¶ôó : 02-575-3825
À̸ÞÀÏ :
katrd@hanmail.net ±³À°Á¾·ù : ³»°úÀÇÇб³À°, ±âŸ
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï : 10000¿ø ÇöÀåµî·Ï : 20000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 13:10~13:35 Platinum/Non-platinum Retreatment ½Å¾Æ¿µ(°¡Å縯ÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 13:35~14:00 Target Agents Ȳ±âÀº(¿ø±¤ÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 14:00~14:25 Immune Checkpoint Inhibitors ÃÖ¼öÀÎ(°í·ÁÀÇ´ë ³»°ú)
ÈÞ½Ä 07-23 ¾Æ³ªÀ̽ºÈ¦ 14:25~14:40 Refreshment ()
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 14:40~15:05 A role for Recombinant G-CSF and GM-CSF in Lung Cancer Á¤Ä¡¿µ(°¡Å縯ÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 15:05~15:30 Immune Evasion of G-CSF and GM-CSF in Lung Cancer Á¤Àç¿í(Ãæ³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 15:30~15:55 Severe Nneutropenia and Dose Reduction: Impact on Survival of Lung Cancer ±è¹ÌÇö(ºÎ»êÀÇ´ë ³»°ú)
ÈÞ½Ä 07-23 ¾Æ³ªÀ̽ºÈ¦ 15:55~16:10 Refreshment ()
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 16:10~16:35 Management of Steroid-Refractory Immune-Related Adverse Events ÀÌÀºÇý(¿¬¼¼ÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 16:35~17:00 Rare but, Critical AE in Patients with Newly Introduced Target Agents ÃÖ¼±ÇÏ(°æºÏÀÇ´ë ³»°ú)
±³À°½Ã°£ 07-23 ¾Æ³ªÀ̽ºÈ¦ 17:00~17:25 Quality-of-Life Outcomes for Neoadjuvant or Adjuvant Chemotherapy in NSCLC ±èÇý·Ã(¿øÀڷº´¿ø)